DXR Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Daxor's net margin of --. Daxor's return on equity of 5.22% beat Perspective Therapeutics's return on equity of --.

Daxor has a consensus price target of --, signalling upside risk potential of 179.94%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Daxor, analysts believe Perspective Therapeutics is more attractive than Daxor.

Daxor has a beta of -0.508, which suggesting that the stock is 150.824% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Daxor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Daxor quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Daxor's net income of -- is lower than Perspective Therapeutics's net income of -$15.1M. Notably, Daxor's price-to-earnings ratio is 27.81x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor is 15.44x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Precision Optics has a net margin of -- compared to Daxor's net margin of -31.24%. Daxor's return on equity of 5.22% beat Precision Optics's return on equity of -34.86%.

Daxor has a consensus price target of --, signalling upside risk potential of 179.94%. On the other hand Precision Optics has an analysts' consensus of -- which suggests that it could fall by --. Given that Daxor has higher upside potential than Precision Optics, analysts believe Daxor is more attractive than Precision Optics.

Daxor has a beta of -0.508, which suggesting that the stock is 150.824% less volatile than S&P 500. In comparison Precision Optics has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.901%.

Daxor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor pays -- of its earnings as a dividend. Precision Optics pays out -- of its earnings as a dividend.

Daxor quarterly revenues are --, which are smaller than Precision Optics quarterly revenues of $4.2M. Daxor's net income of -- is lower than Precision Optics's net income of -$1.3M. Notably, Daxor's price-to-earnings ratio is 27.81x while Precision Optics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor is 15.44x versus 1.68x for Precision Optics. Usually stocks with elevated PS ratios are considered overvalued.

Sanara MedTech has a net margin of -- compared to Daxor's net margin of -13.19%. Daxor's return on equity of 5.22% beat Sanara MedTech's return on equity of -19.67%.

Daxor has a consensus price target of --, signalling upside risk potential of 179.94%. On the other hand Sanara MedTech has an analysts' consensus of $44.00 which suggests that it could grow by 30.88%. Given that Daxor has higher upside potential than Sanara MedTech, analysts believe Daxor is more attractive than Sanara MedTech.

Daxor has a beta of -0.508, which suggesting that the stock is 150.824% less volatile than S&P 500. In comparison Sanara MedTech has a beta of 1.574, suggesting its more volatile than the S&P 500 by 57.373%.

Daxor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanara MedTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor pays -- of its earnings as a dividend. Sanara MedTech pays out -- of its earnings as a dividend.

Daxor quarterly revenues are --, which are smaller than Sanara MedTech quarterly revenues of $21.7M. Daxor's net income of -- is lower than Sanara MedTech's net income of -$2.9M. Notably, Daxor's price-to-earnings ratio is 27.81x while Sanara MedTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor is 15.44x versus 3.64x for Sanara MedTech. Usually stocks with elevated PS ratios are considered overvalued.

Warby Parker has a net margin of -- compared to Daxor's net margin of -2.12%. Daxor's return on equity of 5.22% beat Warby Parker's return on equity of -10.25%.

Daxor has a consensus price target of --, signalling upside risk potential of 179.94%. On the other hand Warby Parker has an analysts' consensus of $22.23 which suggests that it could fall by -11.71%. Given that Daxor has higher upside potential than Warby Parker, analysts believe Daxor is more attractive than Warby Parker.

Daxor has a beta of -0.508, which suggesting that the stock is 150.824% less volatile than S&P 500. In comparison Warby Parker has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Daxor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Daxor pays -- of its earnings as a dividend. Warby Parker pays out -- of its earnings as a dividend.

Daxor quarterly revenues are --, which are smaller than Warby Parker quarterly revenues of $192.4M. Daxor's net income of -- is lower than Warby Parker's net income of -$4.1M. Notably, Daxor's price-to-earnings ratio is 27.81x while Warby Parker's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Daxor is 15.44x versus 4.06x for Warby Parker. Usually stocks with elevated PS ratios are considered overvalued.